How volatile is Merck & Co., Inc.?

Over the past year, Merck & Co., Inc. had an annualised volatility of 29.14%, based on daily closes. Its deepest fall from a high in that time was 11.90%, from February 24, 2026 to April 30, 2026. Its beta against the S&P 500 was 0.13.

What was the biggest price drop for Merck & Co., Inc.?

The deepest fall in our weekly price history since October 2006 was 62.52%, from a high in the week of December 3, 2007 to a low in the week of March 2, 2009. The price regained that high in the week of September 1, 2014.

Which month has historically been best for Merck & Co., Inc.?

Since 2015, November has had the highest average return for Merck & Co., Inc. (+3.71%, up in 7 of 11 years) and September the lowest (-2.51%, up in 3 of 12 years). Past seasonal patterns do not predict future returns.

stock · yahoo

Merck & Co., Inc.

MRK

$145.95

▲ 0.76 (0.52%)

polled · warming up

Below: live stock price for Merck & Co., Inc. (MRK), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Merck & Co., Inc. (MRK) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 73,000 people. Over the past year MRK traded between 82.01 and 156.92 USD. Trailing P/E sits near 115.83 on a market cap of about 360.08B USD. It currently yields 2.33% in dividends.

Day

+0.52%

+0.76

Week

+0.24%

+0.35

Month

-0.63%

-0.92

Year

—

Prev close: $145.19
Volume (24h): $1.64B
Market cap: $360.08B
Currency: USD

Score

40/ 100 · Weak

Coverage: 7/7

Value4
Quality60
Momentum79
Growth36
Risk60
Dividend15
Liquidity25

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 37%Pace +0.20% per bar

+5 bars+20 bars+60 bars+120 bars

+5 bars: 147.124
+20 bars: 148.7594
+60 bars: 149.3969
+120 bars: 149.4204

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0467 USD.

Interpretation

Composite signals look weak. Strength: momentum with weakness: valuation. Price sits in the middle of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

Value
4/100
Value looks fragile — driven by P/E (115.83).
P/E:115.83P/B:8.59PEG:2.73
Quality
60/100
Quality looks solid — driven by Gross margin (75.90%).
ROE:6.96%ROA:11.87%Profit margin:4.77%Gross margin:75.90%
Momentum
79/100
Momentum looks strong — driven by 52w change (69.08%).
52w change:69.08%
Growth
36/100
Growth looks weak — driven by Revenue growth (5.10%).
Revenue growth:5.10%
Risk
60/100
Risk looks solid — driven by Debt / equity (128.41).
Beta:0.22Debt / equity:128.41Short interest:1.15%
Dividend
15/100
Dividend looks fragile — driven by Payout ratio (266.67%).
Dividend yield:2.33%Payout ratio:266.67%
Liquidity
25/100
Liquidity looks fragile — driven by Current ratio (1.32).
Current ratio:1.32Quick ratio:0.74

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 250 days.

Position in range85%

82.01 low156.92 high

Where the price sits between the window low and high.

Volatility (annualised): 29.1%
Max drawdown: -11.9%
Below period high: -7.0%
Best day: +12.60%
Worst day: -4.06%
Up days: 52%
Current streak: 1 up
Typical day swing: 2.4%
Volume vs average: +1%

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above

149.6748 USD+2.55%

Fib 23.6% retracement

Next level below

145.1926 USD-0.52%

Fib 38.2% retracement

Levels derived from: 156.92 high → 126.22 low · 60 bars

Resistance
Fib +161.8% extension
not reached
206.5926 USD
+41.55% from current
Resistance
Fib +100% extension
not reached
187.62 USD
+28.55% from current
Resistance
Fib +61.8% extension
not reached
175.8926 USD
+20.52% from current
Resistance
Fib +27.2% extension
not reached
165.2704 USD
+13.24% from current
Resistance
Fib 23.6% retracement
tested 14×
149.6748 USD
+2.55% from current
Current
145.95 USD
Support
Fib 38.2% retracementNearest
tested 10×
145.1926 USD
-0.52% from current
Support
Fib 50% midpoint
tested 5×
141.57 USD
-3.00% from current
Support
Fib 61.8% retracement
tested 1×
137.9474 USD
-5.48% from current
Support
Fib 78.6% retracement
tested 3×
132.7898 USD
-9.02% from current
Support
Fib −27.2% extension
not reached
117.8696 USD
-19.24% from current
Support
Fib −61.8% extension
not reached
107.2474 USD
-26.52% from current
Support
Fib −100% extension
not reached
95.52 USD
-34.55% from current

How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high: $156.92
52w low: $82.01
52w change: 69.08%
Day high: $147.80
Day low: $145.62
P/E (TTM): 115.83
Forward P/E: 15.71
PEG: 2.73
Price / Book: 8.59
Beta (5Y): 0.22
Enterprise value: 406.9B
EV / Revenue: 6.11
EV / EBITDA: 14.09
EPS (TTM): $1.26
Forward EPS: $9.29
Dividend yield: 2.33%
Dividend rate: $3.40
Payout ratio: 266.67%
Revenue (TTM): 66.57B
EBITDA: 28.87B
Free cash flow: 15.17B
Total cash: 7.14B
Total debt: 53.91B
Debt / Equity: 128.41
Current ratio: 1.32
Quick ratio: 0.74
Profit margin: 4.77%
Gross margin: 75.90%
Return on assets: 11.87%
Return on equity: 6.96%
Shares outstanding: 2.47B
Float: 2.46B

Sector: HealthcareIndustry: Drug Manufacturers - GeneralHQ: United StatesEmployees: 73Kwww.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Analyst & Risk

Consensus

Buy

Mean rating1.78 / 5

Analysts25

Next earnings2026-10-29

Strong buy 5Buy 14Hold 8

Analyst price target

$158.44

Mean target · 25 analysts

+8.6%

upside

Low $105.00Now $145.95High $186.00

Beta (vs S&P 500): 0.22; very stable
52-week change: 69.08%
Short % of float: 1.15%
Short ratio (days): 2.88
Debt / Equity: 128.41; very high leverage
Current ratio: 1.32
Quick ratio: 0.74
ROE: 6.96%
ROA: 11.87%
PEG ratio: 2.73; richly valued
EV / Revenue: 6.11
EV / EBITDA: 14.09
Revenue growth: 5.10%
EBITDA: 28.87B
Free cash flow: 15.17B
Total cash: 7.14B
Total debt: 53.91B
Insider holdings: 0.06%
Institutional: 82.94%

Recent rating changes

2026-10-12CitigroupNeutral → Neutralmain
2026-10-12RBC CapitalSector Perform → Sector Performmain
2026-10-08Cantor FitzgeraldNeutral → Neutralmain
2026-10-07Morgan StanleyOverweight → Overweightmain
2026-10-05JP MorganOverweight → Overweightmain
2026-09-29ScotiabankSector Outperform → Sector Outperformmain
2026-09-10HSBCBuy → Buymain
2026-09-09Leerink PartnersOutperform → Outperformmain

Financial documents

Merck & Co., Inc. performance

Change from the closing price at the start of each period to the latest price.

Period	Start price	Change	Per year
1 week$145.60	$145.60	+0.24%
1 month$146.87	$146.87	-0.63%
3 months$127.50	$127.50	+14.47%
6 months$119.07	$119.07	+22.57%
Year to date$105.26	$105.26	+38.66%
1 year$86.32	$86.32	+69.08%
3 years$104.01	$104.01	+40.32%	+11.89%
5 years$78.33	$78.33	+86.33%	+13.23%
10 years$59.29	$59.29	+146.1%	+9.41%
Since Oct 2006$43.98	$43.98	+231.9%	+6.19%

Periods up to a year use daily closes, longer ones weekly closes. “Per year” is the compound annual growth rate.

Price change only; dividends are not included.

Merck & Co., Inc. all-time high and low

Highest since Oct 2006

$156.92

Aug 25, 2026

6.99% below the high

Lowest since Oct 2006

$19.13

week of Mar 9, 2009

662.9% above the low

52-week range

85%

Low

$82.01

Nov 4, 2025

High

$156.92

Aug 25, 2026

The latest price sits at 85% of this range.

Highs and lows include intraday prices.

Merck & Co., Inc. risk metrics

Past year of daily closes unless stated otherwise.

Volatility (1 year, annualised): 29.14%; How large price swings have been: the standard deviation of daily returns, scaled up to a year.
Max drawdown (1 year): -11.90%; Feb 24, 2026 → Apr 30, 2026 · Recovered on Jun 25, 2026.; The deepest fall from a previous high to a later low over the past year.
Max drawdown (since Oct 2006): -62.52%; Dec 2007 → Mar 2009 · Recovered in the week of Sep 1, 2014.; The same measure across the whole weekly price history.
Sharpe ratio (risk-free rate 0): 1.95; Average daily return divided by its volatility, annualised: higher means more return for each unit of risk over the past year.
Beta vs S&P 500 (1 year): 0.13; On average, Merck & Co., Inc. moved 0.13% for each 1% move in the S&P 500 on the same day.

Merck & Co., Inc. drawdown from peak

How far the price stood below its previous high, based on weekly closes since Oct 2006.

Merck & Co., Inc. seasonality

Monthly returns by year, from month-end closes: daily data for the past year, weekly closes before that.

Merck & Co., Inc. seasonality
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	+4.8%	+12%	-2.9%	-9.2%	+8.7%	+8.2%	+1.3%	+13%	-1.7%	+0.4%*			+39%*
2025	-0.9%	-6.6%	-3.3%

Merck & Co., Inc. price history

Yearly open, high, low and close, newest first.

Merck & Co., Inc. price history
Year	Open	High	Low	Close	Change
2026YTD	$105.53	$156.92	$104.43	$145.95	+38.66%
2025	$99.57	$107.59	$73.31	$105.26	+5.58%
2024	$109.16	$134.63	$94.48	$99.70	-8.55%
2023	$110.41	$119.65	$99.14	$109.02	-1.74%
2022	$76.58	$112.89	$72.88	$110.95	+44.77%

Frequently asked questions about Merck & Co., Inc.

What is the price of Merck & Co., Inc. today?

As of October 18, 2026, the price of Merck & Co., Inc. is $145.95, up 0.52% from the previous close.

What is the all-time high of Merck & Co., Inc.?

The highest price for Merck & Co., Inc. in our data, which starts in October 2006, is $156.92, reached on August 25, 2026. At $145.95, the latest price is 6.99% below it.

How much has Merck & Co., Inc. gained this year?

Calculated from historical closing prices — daily for the past year, weekly before that — and refreshed as new prices arrive. Past performance does not predict future returns. Not investment advice.


Average	+1.6%	-0.6%	+0.5%	+0.6%	+1.5%	+1.3%	+0.1%	+3.2%	-2.5%	+1.1%	+3.7%	0.0%	+7.4%
Years up	58%	42%	42%	50%	75%	58%	67%	58%	25%	45%	64%	55%	45%

Year	Open	High	Low	Close	Change
2021	$78.24	$91.40	$68.44	$76.64	-1.81%
2020	$87.34	$87.92	$62.26	$78.05	-10.60%
2019	$72.35	$88.40	$68.75	$87.31	+21.40%
2018	$54.00	$76.52	$50.41	$71.92	+33.94%
2017	$56.44	$63.74	$51.17	$53.69	-4.42%
2016	$49.63	$62.46	$45.77	$56.17	+11.45%
2015	$54.82	$60.71	$43.60	$50.40	-8.58%
2014	$47.46	$59.35	$47.04	$55.13	+16.05%
2013	$38.44	$48.11	$38.19	$47.51	+22.51%
2012	$36.15	$45.80	$35.22	$38.78	+7.80%
2011	$34.63	$36.16	$28.12	$35.97	+4.61%
2010	$35.13	$39.66	$29.29	$34.39	-1.37%
2009	$27.78	$36.66	$19.13	$34.87	+26.00%
2008	$55.68	$58.38	$21.77	$27.67	-50.60%
2007	$42.01	$58.80	$40.41	$56.02	+34.66%
2006from October	$43.38	$44.25	$40.35	$41.60	—

Month	Close	Change
September 2026	$145.31	-1.66%
August 2026	$147.76	+13.49%
July 2026	$130.20	+1.32%
June 2026	$128.50	+8.24%
May 2026	$118.72	+8.74%
April 2026	$109.18	-9.24%

Month	Close	Change
March 2026	$120.29	-2.85%
February 2026	$123.82	+12.29%
January 2026	$110.27	+4.76%
December 2025	$105.26	+0.41%
November 2025	$104.83	+21.92%
October 2025	$85.98	+9.45%

Merck & Co., Inc.

Financials

Analyst & Risk

Recent rating changes

Financial documents

Merck & Co., Inc. performance

Merck & Co., Inc. all-time high and low

52-week range

Merck & Co., Inc. risk metrics

Merck & Co., Inc. drawdown from peak

Merck & Co., Inc. seasonality

Merck & Co., Inc. price history

Frequently asked questions about Merck & Co., Inc.

What is the price of Merck & Co., Inc. today?

What is the all-time high of Merck & Co., Inc.?

How much has Merck & Co., Inc. gained this year?

Recent news

Learn the terms

Live discussion

Merck & Co., Inc. performance

Merck & Co., Inc. all-time high and low

52-week range

Merck & Co., Inc. risk metrics

Merck & Co., Inc. drawdown from peak

Merck & Co., Inc. seasonality

Merck & Co., Inc. price history

Frequently asked questions about Merck & Co., Inc.

What is the price of Merck & Co., Inc. today?

What is the all-time high of Merck & Co., Inc.?

How much has Merck & Co., Inc. gained this year?

Merck & Co., Inc. month-end closes

How volatile is Merck & Co., Inc.?

What was the biggest price drop for Merck & Co., Inc.?

Which month has historically been best for Merck & Co., Inc.?